Valneva shores up balance sheet after mixed trial results
Vaccine specialist Valneva has sold new shares worth €84 million as it moves to strengthen its balance sheet in the wake of mixed results for…
Valneva
Valneva extends loans after chikungunya jab concerns
Vaccine specialist Valneva has refinanced its debt and cut its revenue forecast for this year after the US FDA suspended the licence for its chikungunya…